Luigi Messori
#162,350
Most Influential Person Now
Researcher
Luigi Messori's AcademicInfluence.com Rankings
Download Badge
Physics
Luigi Messori's Degrees
- PhD Physics University of Bologna
- Masters Physics University of Bologna
- Bachelors Physics University of Bologna
Why Is Luigi Messori Influential?
(Suggest an Edit or Addition)Luigi Messori's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs (2009) (453)
- Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies (2010) (374)
- Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. (2000) (295)
- Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. (2004) (260)
- Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds. (2008) (246)
- Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. (2008) (226)
- Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties. (2002) (223)
- Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions. (2004) (181)
- Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives. (2010) (179)
- NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry (2019) (175)
- Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands. (2006) (165)
- The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. (1994) (165)
- Molecular mechanisms and proposed targets for selected anticancer gold compounds. (2011) (153)
- New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications (2008) (147)
- ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. (2007) (141)
- Aluminum, copper, iron and zinc differentially alter amyloid-Aβ(1-42) aggregation and toxicity. (2011) (134)
- Metal Ion Physiopathology in Neurodegenerative Disorders (2009) (128)
- A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition (2011) (127)
- Challenges associated with metal chelation therapy in Alzheimer's disease. (2009) (124)
- Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study (2009) (121)
- Cisplatin binding to proteins: A structural perspective (2016) (117)
- Gold(III) compounds as anticancer drugs (2007) (115)
- A comparative study of aluminum(III), gallium(III), indium(III), and thallium(III) binding to human serum transferrin (2002) (112)
- A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin. (2000) (111)
- Mechanisms of cytotoxicity of selected organogold(III) compounds. (2005) (111)
- Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. (1999) (111)
- Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. (2009) (103)
- DNA as a possible target for antitumor ruthenium(III) complexes. (2000) (101)
- Structural investigation of cisplatin-protein interactions: selective platination of His19 in a cuprozinc superoxide dismutase. (2006) (96)
- Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties. (2008) (95)
- Formation of Supramolecular Structures between DNA and Starburst Dendrimers Studied by EPR, CD, UV, and Melting Profiles (2000) (93)
- Exploring metallodrug–protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound (2009) (91)
- Cisplatin binding to human serum albumin: a structural study. (2015) (90)
- Interactions of selected gold(III) complexes with calf thymus DNA. (2001) (88)
- Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c (2006) (83)
- Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin (2003) (82)
- Gold complexes in the treatment of rheumatoid arthritis. (2004) (81)
- Use of Hydrophobic Ligands for the Stabilization of Low-Valent Transition Metal Complexes. 1. The Effect of N-Methylation of Linear Tetraazaalkane Ligands on the Properties of Their Copper Complexes (1995) (81)
- Chelation therapy for neurodegenerative diseases (2009) (80)
- Reactions of gold(III) complexes with serum albumin. (2003) (79)
- Thioredoxin reductase, an emerging target for anticancer metallodrugs (2011) (79)
- Mass spectrometric analysis of ubiquitin–platinum interactions of leading anticancer drugs: MALDI versus ESI (2007) (78)
- A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins. (2004) (78)
- Antimalarial properties of green tea. (2007) (78)
- Potential pathogenic role of β-amyloid1–42–aluminum complex in Alzheimer's disease ☆ (2008) (78)
- ESI–MS Characterisation of Protein Adducts of Anticancer Ruthenium(II)‐Arene PTA (RAPTA) Complexes (2007) (77)
- Determinants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G-Quadruplex: a Joint ESI MS and XRD Investigation. (2016) (75)
- Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers (2003) (75)
- Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment (2005) (73)
- Trace copper(II) or zinc(II) ions drastically modify the aggregation behavior of amyloid-beta1-42: an AFM study. (2010) (73)
- INVESTIGATION OF CU2CO2SOD AND ITS ANION DERIVATIVES. PROTON NMR AND ELECTRONIC SPECTRA (1985) (73)
- Crystal structure and solution chemistry of the cytotoxic complex 1,2-dichloro(o-phenanthroline)gold(III) chloride (2000) (72)
- Synthesis, structural characterization, solution behavior, and in vitro antiproliferative properties of a series of gold complexes with 2-(2'-pyridyl)benzimidazole as ligand: comparisons of gold(III) versus gold(I) and mononuclear versus binuclear derivatives. (2012) (72)
- Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT. (2010) (71)
- Identification of the iron ions of high potential iron protein from Chromatium vinosum within the protein frame through two-dimensional NMR experiments (1992) (71)
- Chemistry and biology of two novel gold(I) carbene complexes as prospective anticancer agents. (2014) (70)
- [Au2(phen(2Me))2(μ-O)2](PF6)2, a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties. (2010) (70)
- A BINOL-based chiral polyammonium receptor for highly enantioselective recognition and fluorescence sensing of (S,S)-tartaric acid in aqueous solution. (2012) (70)
- Auranofin, Et3PAuCl, and Et3PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study. (2017) (68)
- The mode of action of anticancer gold-based drugs: a structural perspective. (2013) (67)
- Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies. (2008) (66)
- fac-{Ru(CO)(3)}(2+) selectively targets the histidine residues of the beta-amyloid peptide 1-28. Implications for new Alzheimer's disease treatments based on ruthenium complexes. (2010) (66)
- Coordination modes of histidine. 10. Iron(III) tyrosinate models. Synthesis and spectroscopic and stereochemical studies of iron(III) complexes of N-salicylidene-L-amino acids (1987) (66)
- The reaction of artemisinins with hemoglobin: a unified picture. (2006) (64)
- Iridium(I) Compounds as Prospective Anticancer Agents: Solution Chemistry, Antiproliferative Profiles and Protein Interactions for a Series of Iridium(I) N-Heterocyclic Carbene Complexes. (2016) (63)
- Simple and rapid physico-chemical methods to examine action of antimalarial drugs with hemin: its application to Artemisia annua constituents. (2002) (62)
- Solution chemistry and cytotoxic properties of novel organogold(III) compounds. (2004) (62)
- The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes. (2003) (61)
- Protein Metalation by Anticancer Metallodrugs: A Joint ESI MS and XRD Investigative Strategy. (2017) (60)
- Decomposition of ascorbic acid in the presence of cadmium ions leads to formation of a polymeric cadmium oxalate species with peculiar structural features. (2002) (58)
- Metal compounds as inhibitors of β-amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer's disease (2012) (58)
- Insights on the mechanism of thioredoxin reductase inhibition by gold N-heterocyclic carbene compounds using the synthetic linear selenocysteine containing C-terminal peptide hTrxR(488-499): an ESI-MS investigation. (2014) (58)
- Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study (2010) (57)
- Cisplatin binding to proteins: molecular structure of the ribonuclease a adduct. (2014) (55)
- Gold(III) Compounds as New Family of Anticancer Drugs (2003) (54)
- Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action. (2009) (54)
- Modeling of copper(II) sites in proteins based on histidyl and glycyl residues. (2003) (53)
- Gold(III) compounds as potential antitumor agents: Cytotoxicity and DNA binding properties of some selected polyamine-gold(III) complexes (1998) (53)
- Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections (2014) (53)
- Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity. (2008) (52)
- Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm). (1997) (52)
- Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme. (2014) (51)
- Peculiar features in the crystal structure of the adduct formed between cis-PtI2(NH3)2 and hen egg white lysozyme. (2013) (50)
- Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis. (2010) (50)
- Gold complexes as antitumor agents. (2004) (48)
- Speciation of metal-based nanomaterials in human serum characterized by capillary electrophoresis coupled to ICP-MS: a case study of gold nanoparticles. (2015) (48)
- Promising in Vitro anti-Alzheimer Properties for a Ruthenium(III) Complex. (2013) (48)
- Interactions of two cytotoxic organotin(IV) compounds with calf thymus DNA. (2001) (48)
- Cisplatin encapsulation within a ferritin nanocage: a high-resolution crystallographic study. (2016) (48)
- Unravelling the chemical nature of copper cuprizone. (2007) (48)
- Binding of Antitumor Ruthenium(III) Complexes to Plasma Proteins (2000) (47)
- Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: the binding of [trans-RuCl4(Im)(dimethylsulfoxide)][ImH] (Im = imidazole) to bovine serum albumin. (2008) (47)
- Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer. (2019) (47)
- Formation of titanium(IV) transferrin by reaction of human serum apotransferrin with titanium complexes (1999) (47)
- Recent progress in the application of analytical techniques to anticancer metallodrug proteomics (2011) (47)
- Spectroscopic and potentiometric study of the SOD mimic system copper(II)/acetyl-L-histidylglycyl-L-histidylglycine. (2002) (47)
- The Interaction of the Antitumor Complexes Na[trans-RuCl4 (DMSO)(Im)] and Na[trans-RuCl4(DMSO)(Ind)] With Apotransferrin: a Spectroscopic Study (1996) (47)
- Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound. (2007) (46)
- Cytotoxicity and DNA binding properties of a chloro glycylhistidinate gold(III) complex (GHAu). (2000) (46)
- New platinum-oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. (2010) (46)
- Comparison of the Antiproliferative Activity of Two Antitumour Ruthenium(III) Complexes With Their Apotransferrin and Transferrin-Bound Forms in a Human Colon Cancer Cell Line (1996) (45)
- 1H-NMR studies on partially and fully reduced 2(4Fe-4S) ferredoxin from Clostridium pasteurianum. (1992) (45)
- Unusual structural features in the lysozyme derivative of the tetrakis(acetato)chloridodiruthenium(II,III) complex. (2014) (45)
- Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c (2007) (44)
- 2D 1H NMR studies of oxidized 2(Fe4S4) ferredoxin from Clostridium pasteurianum (1991) (43)
- The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells (2017) (43)
- Protein-binding Properties of two Antitumour Ru(III) Complexes to Human Apotransferrin and Apolactoferrin (1994) (43)
- Size dependent biological profiles of PEGylated gold nanorods. (2014) (43)
- Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c. (2007) (42)
- Protein metalation by metal-based drugs: X-ray crystallography and mass spectrometry studies. (2017) (42)
- Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes. (2003) (42)
- Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme (2012) (41)
- Proton NMR studies of the cobalt(II)-metallothionein system (1989) (40)
- Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A. (2004) (40)
- Oxaliplatin vs. cisplatin: competition experiments on their binding to lysozyme. (2015) (40)
- Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: a comparative proteomic study (2018) (40)
- Interactions of gold-based drugs with proteins: crystal structure of the adduct formed between ribonuclease A and a cytotoxic gold(III) compound. (2014) (39)
- Auranofin and its Analogues Show Potent Antimicrobial Activity against Multidrug‐Resistant Pathogens: Structure–Activity Relationships (2018) (39)
- Design, synthesis and characterisation of new chimeric ruthenium(II)-gold(I) complexes as improved cytotoxic agents. (2015) (39)
- cis-Pt I2(NH3)2: a reappraisal. (2015) (38)
- Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. (2011) (38)
- Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds. (2012) (38)
- Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems. (2015) (38)
- Exploring the reactions of β-amyloid (Aβ) peptide 1-28 with Al(III) and Fe(III) ions. (2011) (37)
- ESI MS studies highlight the selective interaction of Auranofin with protein free thiols. (2020) (37)
- The X‐ray Structure of the Adduct between NAMI‐A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins (2010) (37)
- Solution NMR Structure of a Ligand/Hybrid-2-G-Quadruplex Complex Reveals Rearrangements that Affect Ligand Binding. (2017) (37)
- Potential pathogenic role of beta-amyloid(1-42)-aluminum complex in Alzheimer's disease. (2008) (36)
- The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics. (2013) (36)
- The X-ray structure of the complex formed in the reaction between oxaliplatin and lysozyme. (2014) (35)
- fac-{Ru(CO)3}2+-core complexes and design of metal-based drugs. synthesis, structure, and reactivity of Ru-thiazole derivative with serum proteins and absorption-release studies with acryloyl and silica hydrogels as carriers in physiological media. (2007) (35)
- Reactions of Auranofin and Its Pseudohalide Derivatives with Serum Albumin Investigated through ESI-Q-TOF MS. (2018) (35)
- Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: solution behavior, reactions with model proteins, antiproliferative properties. (2012) (34)
- Synthesis, molecular structure and solution chemistry of the iridium(III) complex imidazolium [trans(bisimidazole)tetrachloro iridate(III)] (IRIM) (2001) (34)
- Cytotoxicity, DNA damage, and cell cycle perturbations induced by two representative gold(III) complexes in human leukemic cells with different cisplatin sensitivity. (2001) (34)
- Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs (2020) (34)
- Study of ruthenium(II) complexes with anticancer drugs as ligands. Design of metal-based phototherapeutic agents. (2003) (34)
- A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of Auranofin (2020) (34)
- The copper(II) coordination abilities of three novel cyclic tetrapeptides with -His-Xaa-His- motif. (2007) (34)
- NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels. (2014) (33)
- Interactions of gold-based drugs with proteins: the structure and stability of the adduct formed in the reaction between lysozyme and the cytotoxic gold(III) compound Auoxo3. (2014) (33)
- Structure and DNA binding properties of the gold(III) complex (AuCl2(esal)) (1999) (33)
- Proteomic and metallomic strategies for understanding the mode of action of anticancer metallodrugs. (2010) (33)
- Interactions of carboplatin and oxaliplatin with proteins: Insights from X-ray structures and mass spectrometry studies of their ribonuclease A adducts. (2015) (33)
- Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c). (2014) (33)
- Reactivity and biological properties of a series of cytotoxic PtI2(amine)2 complexes, either cis or trans configured. (2012) (33)
- Selection and characterization of a human ovarian cancer cell line resistant to auranofin (2017) (33)
- Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin. (1998) (33)
- Tl as an NMR probe for the investigation of transferrin (1983) (32)
- Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent. (2019) (32)
- DOTAP/DOPE and DC-Chol/DOPE lipoplexes for gene delivery studied by circular dichroism and other biophysical techniques. (2007) (32)
- Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives. (2016) (32)
- Metal‐Based Compounds as Prospective Antileishmanial Agents: Inhibition of Trypanothione Reductase by Selected Gold Complexes (2013) (31)
- Spectral characterization of ruthenium (III) transferrin. (1993) (31)
- Peculiar mechanistic and structural features of the carboplatin–cytochrome c system revealed by ESI-MS analysis (2008) (31)
- Platinum(II) Complexes with O,S Bidentate Ligands: Biophysical Characterization, Antiproliferative Activity, and Crystallographic Evidence of Protein Binding. (2015) (31)
- Cytotoxic activity and protein binding through an unusual oxidative mechanism by an iridium(I)-NHC complex. (2015) (31)
- The copper(II) binding properties of the cyclic peptide c(HGHK). (2004) (31)
- Novel platinum(II) compounds with O,S bidentate ligands: synthesis, characterization, antiproliferative properties and biomolecular interactions. (2014) (30)
- Investigation of the effects of copper ions on protein aggregation using a model system (2004) (30)
- Molecular Recognition of Metal Complexes by DNA: A Comparative Study of the Interactions of the Parent Complexes [PtCl(TERPY)]Cl and [AuCl(TERPY)]Cl 2 with Double Stranded DNA (2005) (30)
- Structural features of a new dinuclear platinum(II) complex with significant antiproliferative activity. (2003) (30)
- PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features. (2017) (30)
- The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years? (2018) (29)
- Protein targets for anticancer gold compounds: mechanistic inferences. (2011) (29)
- Rapid purification of gold nanorods for biomedical applications (2014) (29)
- Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials. (2009) (29)
- Carbon-13 NMR study of the synergistic anion in transferrins (1986) (29)
- Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: biological and pharmacological implications. (2012) (29)
- Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. (2011) (29)
- Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel "Rule-Breaker" Iodidoplatinum(II) Complex. (2010) (28)
- The X-ray structure of the primary adducts formed in the reaction between cisplatin and cytochrome c. (2015) (28)
- 2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds. (2012) (27)
- A first-in-class and a fished out anticancer platinum compound: cis-[PtCl2(NH3)2] and cis-[PtI2(NH3)2] compared for their reactivity towards DNA model systems. (2016) (27)
- Protein Recognition of Gold-Based Drugs: 3D Structure of the Complex Formed When Lysozyme Reacts with Aubipy(c.). (2014) (27)
- Impact of ring size on the copper(II) coordination abilities of cyclic tetrapeptides. (2009) (26)
- Proanthocyanidin glycosides from the leaves of Quercus ilex L. (Fagaceae) (2009) (26)
- Gold(III) complexes with hydroxyquinoline, aminoquinoline and quinoline ligands: Synthesis, cytotoxicity, DNA and protein binding studies. (2015) (26)
- Gold(III) complexes as a new family of cytotoxic and antitumor agents (2002) (26)
- X-ray absorption spectroscopy studies of the adducts formed between cytotoxic gold compounds and two major serum proteins (2011) (26)
- Butyltin(IV) Benzoates: Inhibition of Thioredoxin Reductase, Tumor Cell Growth Inhibition, and Interactions with Proteins (2013) (26)
- Structure-function relationships within Keppler-type antitumor ruthenium(III) complexes: the case of 2-aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)]. (2005) (25)
- Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments. (2017) (25)
- Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability. (2011) (25)
- Cisplatin Binding Sites in Human H-Chain Ferritin. (2017) (24)
- A Fluorescent Silver(I) Carbene Complex with Anticancer Properties: Synthesis, Characterization, and Biological Studies (2018) (24)
- Interactions between anticancer trans-platinum compounds and proteins: crystal structures and ESI-MS spectra of two protein adducts of trans-(dimethylamino)(methylamino)dichloridoplatinum(II). (2014) (24)
- The cisplatin/serum albumin system: A reappraisal (2019) (24)
- Metal-induced conformational heterogeneity of transferrins: a spectroscopic study of indium(III) and other metal(III)-substituted transferrins. (1995) (23)
- Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PEt3)I: A Theoretical and Experimental Study (2020) (23)
- Ru-Based CO releasing molecules with azole ligands: interaction with proteins and the CO release mechanism disclosed by X-ray crystallography. (2017) (23)
- New gold carbene complexes as candidate anticancer agents (2016) (23)
- New copper(II)/cyclic tetrapeptide system that easily oxidizes to copper(III) under atmospheric oxygen. (2007) (23)
- Solution studies of the antitumor complex dichloro 1,2-propylendiaminetetraacetate ruthenium (III) and of its interactions with proteins. (1998) (22)
- Synthesis, spectroscopic and DFT structural characterization of two novel ruthenium(III) oxicam complexes. In vivo evaluation of anti-inflammatory and gastric damaging activities. (2014) (22)
- Chemistry and biology of three representative gold(III) compounds as prospective anticancer agents (2012) (21)
- Interaction of a gold(i) dicarbene anticancer drug with human telomeric DNA G-quadruplex: solution and computationally aided X-ray diffraction analysis. (2018) (21)
- Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities. (2014) (21)
- Reactions of Medicinal Gold(III) Compounds With Proteins and Peptides Explored by Electrospray Ionization Mass Spectrometry and Complementary Biophysical Methods (2020) (21)
- Antiproliferative properties and biomolecular interactions of three Pd(II) and Pt(II) complexes. (2016) (21)
- Structure of a terbium(III)-quinizarine complex: the first crystallographic model for metalloanthracyclines. (2003) (21)
- 1H NMR spectroscopic characterization of binary and ternary complexes of cobalt(II) carboxypeptidase A with inhibitors. (1988) (20)
- Structural effects of titanium citrate on the human erythrocyte membrane. (2005) (20)
- The C2 variant of human serum transferrin retains the iron binding properties of the native protein. (2005) (20)
- Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties. (2016) (19)
- Structural Characterization of a Gold/Serum Albumin Complex. (2019) (19)
- Kinetic studies on metal removal from transferrins by pyrophosphate. Investigation on iron(III) and manganese(III) derivatives (1988) (19)
- {Ru(CO)x}-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivo. (2017) (19)
- Solution chemistry and DNA binding properties of MEN 10755, a novel disaccharide analogue of doxorubicin. (2001) (19)
- A theoretical analysis of the 1H nuclear magnetic relaxation dispersion profiles of diferric transferrin (1995) (19)
- The disaccharide anthracycline MEN 10755 binds human serum albumin to a non-classical drug binding site. (2002) (18)
- Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents (2017) (18)
- Spectrophotometric and ESI-MS/HPLC studies reveal a common mechanism for the reaction of various artemisinin analogues with hemin. (2003) (17)
- The NAMI A - human ferritin system: a biophysical characterization. (2018) (17)
- Crystallographic evidence for decomposition of dimethylformamide in the presence of ruthenium(III) chloride (2003) (17)
- {Ru(CO)x}-core complexes with selected azoles: Synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells (2014) (17)
- Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles (2016) (17)
- Selected gold compounds cause pronounced inhibition of Falcipain 2 and effectively block P. falciparum growth in vitro. (2011) (17)
- Solution behaviour and biomolecular interactions of two cytotoxic trans-platinum(II) complexes bearing aliphatic amine ligands. (2009) (17)
- Evidence of a metal-synergistic anion bond in thallium(III) transferrin (1988) (17)
- Short-chain oligopeptides with copper(II) binding properties: The impact of specific structural modifications on the copper(II) coordination abilities. (2009) (16)
- Na/K-ATPase as a target for anticancer metal based drugs: insights into molecular interactions with selected gold(iii) complexes. (2017) (16)
- Interactions of selected gold(III) complexes with DNA G quadruplexes. (2015) (16)
- A novel class of peptides with facilitating action on neuronal nicotinic receptors of rat chromaffin cells in vitro: functional and molecular dynamics studies. (2002) (16)
- Reactions of cisplatin and cis-[PtI2(NH3)2] with molecular models of relevant protein sidechains: A comparative analysis. (2020) (16)
- Induction of a Four‐Way Junction Structure in the DNA Palindromic Hexanucleotide 5′‐d(CGTACG)‐3′ by a Mononuclear Platinum Complex (2019) (16)
- Coordination compounds and life processes (1992) (15)
- pH-dependent properties of cobalt(II) carboxypeptidase A-inhibitor complexes. (1992) (15)
- The fate of differently functionalized gold nanorods in human serum: A response from capillary electrophoresis-inductively coupled plasma mass spectrometry. (2017) (15)
- Synthesis and Mode of Action Studies on Iridium(I)–NHC Anticancer Drug Candidates (2018) (15)
- A 1H NMR study of the complex of cobalt(II) with 2,5,8,11-tetramethyl-2,5,8,11-tetraazadodecane in aerated aqueous solutions (1995) (15)
- Anticancer Ruthenium(III) Complex KP1019 Interferes with ATP‐Dependent Ca2+ Translocation by Sarco‐Endoplasmic Reticulum Ca2+‐ATPase (SERCA) (2014) (15)
- Proton NMR spectra of the Co4S11 cluster in metallothioneins: a theoretical model (1989) (15)
- Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties. (2020) (15)
- Cell and Cell-Free Mechanistic Studies on Two Gold(III) Complexes with Proven Antitumor Properties (2017) (15)
- Elucidating the reactivity of Pt(II) complexes with (O,S) bidentate ligands towards DNA model systems. (2016) (14)
- Effects of two representative antitumor ruthenium(III) complexes on thermal denaturation profiles of DNA (2000) (14)
- Spectral characterization of vanadium-transferrin systems. (1985) (14)
- The metal-binding properties of ovotransferrin. An investigation of cobalt(II) derivatives. (1986) (14)
- A two-dimensional NMR study of Co(II)7 rabbit liver metallothionein. (1993) (14)
- Structural evidences for a secondary gold binding site in the hydrophobic box of lysozyme (2015) (13)
- Proteomics as a tool to disclose the cellular and molecular mechanisms of selected anticancer gold compounds (2021) (13)
- Biological Properties of IRIM, the Iridium(III) Analogue of (Imidazolium (Bisimidazole) Tetrachlororuthenate) (ICR) (2000) (13)
- Evidence that the antiproliferative effects of auranofin in Saccharomyces cerevisiae arise from inhibition of mitochondrial respiration. (2015) (13)
- Tuning the interactions of PEG-coated gold nanorods with BSA and model proteins through insertion of amino or carboxylate groups. (2015) (13)
- Selective interaction of ferricyanide with cluster I of Clostridium pasteurianum 2[Fe4S4] ferredoxin (1993) (13)
- The leading established metal-based drugs: a revisitation of their relevant physico-chemical data (2019) (12)
- Alkyne Functionalization of a Photoactivated Ruthenium Polypyridyl Complex for Click-Enabled Serum Albumin Interaction Studies (2020) (12)
- The pH dependent properties of metallotransferrins: a comparative study (1997) (12)
- A water 17O NMR study of the pH dependent properties of superoxide dismutase. (1981) (12)
- Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. (2010) (12)
- Protein Metalation by Inorganic Anticancer Drugs (2020) (11)
- Cobalt(II) as an NMR probe for the investigation of the coordination sites of conalbumin. (1984) (11)
- Transferrin: From Inorganic Biochemistry to Medicine (1994) (11)
- Antiplasmodial Effects of a few Selected Natural Flavonoids and their Modulation of Artemisinin Activity (2008) (11)
- STRUCTURE AND CYTOTOXIC PROPERTIES OF SOME SELECTED GOLD(III) COMPLEXES (1999) (11)
- Nitrate as a probe of cytochrome c surface: crystallographic identification of crucial "hot spots" for protein-protein recognition. (2014) (11)
- Protein interactions of dirhodium tetraacetate: a structural study. (2020) (11)
- 1H NMR detection of CoOH2 .dblharw. CoOH interconversions in high-spin cobalt(II) complexes (1982) (11)
- Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication. (2015) (11)
- 1H-NMR investigation of the interaction of the amino terminal domain of the LexA repressor with a synthetic half-operator. (1991) (11)
- Reactions of a tetranuclear Pt-thiosemicarbazone complex with model proteins. (2018) (11)
- Synthesis, DNA binding studies, and antiproliferative activity of novel Pt(II)-complexes with an L-alanyl-based ligand. (2019) (11)
- Dinuclear Gold(III) Complexes as Potential Anticancer Agents: Structure, Reactivity and Biological Profile of a Series of Gold(III) Oxo-Bridged Derivatives~!2009-12-08~!2010-01-15~!2010-03-25~! (2010) (10)
- ESI–MS studies of the reactions of novel platinum(II) complexes containing O,O′-chelated acetylacetonate and sulfur ligands with selected model proteins (2017) (10)
- New platinum(II) and palladium(II) complexes with substituted terpyridine ligands: synthesis and characterization, cytotoxicity and reactivity towards biomolecules (2018) (10)
- CD and EXAFS study of the interaction between phosvitin and copper(II) ions (1988) (10)
- The combined activation of K Ca 3.1 and inhibition of K v 11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells (2017) (9)
- The Influence of Auranofin, a Clinically Established Antiarthritic Gold Drug, on Bone Metabolism: Analysis of Its Effects on Human Multipotent Adipose‐Derived Stem Cells, Taken as a Model (2008) (9)
- A case of extensive protein platination: the reaction of lysozyme with a Pt(ii)-terpyridine complex. (2018) (9)
- Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles (2016) (9)
- Effect of nonsynergistic anions on copper transferrin (1988) (9)
- EXAFS investigation on the iron(III) binding sites of hen phosvitin (1990) (9)
- Effects of chronic treatment with sodium tetrachloroaurate(III) in mice and membrane models. (2004) (9)
- Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones. (2011) (9)
- Interaction of phosphate and pyrophosphate with cobalt(II) carboxypeptidase (1990) (9)
- Inhibition of Na(+)/K(+)-ATPase and cytotoxicity of a few selected gold(III) complexes. (2014) (9)
- Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(II) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage. (2011) (8)
- Synthesis, characterization and DNA interactions of [Pt3(TPymT)Cl3], the trinuclear platinum(II) complex of the TPymT ligand. (2018) (8)
- Gold(III) Compounds as Anticancer Agents: Relevance of Gold—Protein Interactions for Their Mechanism of Action (2008) (8)
- On the Different Mode of Action of Au(I)/Ag(I)-NHC Bis-Anthracenyl Complexes Towards Selected Target Biomolecules (2020) (8)
- New Insights into the Molecular Mechanisms of Selected Anticancer MetalCompounds through Bioinformatic Analysis of Proteomic Data (2013) (8)
- Synthesis and characterisation of two new catechol-based iron(III) ion-sequestering agents (1998) (7)
- cis-Pt I 2 ( NH 3 ) 2 : a Reappraisal (2015) (7)
- Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin. (2015) (7)
- Reaction with Proteins of a Five-Coordinate Platinum(II) Compound (2019) (7)
- Potential antitumor gold drugs: DFT and XANES studies of local atomic and electronic structure (2009) (6)
- EXAFS studies on the oxalate adduct of iron transferrin (1992) (6)
- Arsenoplatin-Ferritin Nanocage: Structure and Cytotoxicity (2021) (6)
- Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles (2021) (6)
- Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation (2018) (6)
- Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers. (2015) (6)
- Au2trien: a dinuclear gold(III) complex with unprecedented structura features. (2002) (6)
- The electrochemical profiles of Auranofin and Aubipyc, two representative medicinal gold compounds: A comparative study. (2019) (6)
- Frontiers in 2D NMR of paramagnetic metalloproteins (1993) (6)
- Auranofin and its analogs as prospective agents for the treatment of colorectal cancer (2022) (6)
- Controlling with light the interaction between trans-tetrapyridyl ruthenium complexes and an oligonucleotide. (2018) (6)
- Erratum to: CE Separation and ICP-MS Detection of Gold Nanoparticles and Their Protein Conjugates (2017) (6)
- Antiproliferative Properties of a Few Auranofin-Related Gold(I) and Silver(I) Complexes in Leukemia Cells and their Interferences with the Ubiquitin Proteasome System (2020) (6)
- Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin (2019) (6)
- Au2phen and Auoxo6, Two Dinuclear Oxo-Bridged Gold(III) Compounds, Induce Apoptotic Signaling in Human Ovarian A2780 Cancer Cells (2021) (6)
- [Au(9-methylcaffein-8-ylidene)2 ]+ /DNA Tel23 System: Solution, Computational, and Biological Studies. (2017) (6)
- Redox proteome analysis of auranofin exposed ovarian cancer cells (A2780) (2022) (5)
- 1H NMR studies on lanthanides substituted transferrins. (1991) (5)
- Influence of cis- and trans-diamminedichloroplatinum(II) binding on the helix-coil transition of DNAs with different GC content (1998) (5)
- In Vitro Anti-SARS-CoV-2 Activity of Selected Metal Compounds and Potential Molecular Basis for Their Actions Based on Computational Study (2021) (5)
- Kinetic and structural analysis of the inactivation of urease by mixed-ligand phosphine halide Ag(I) complexes. (2021) (5)
- Antiplasmodial activity of papaya leaf decoction and its synergistic effects in combination with artemisinin (2009) (5)
- Diruthenium Diacetate Catalysed Aerobic Oxidation of Hydroxylamines and Improved Chemoselectivity by Immobilisation to Lysozyme (2017) (5)
- The influence of oxo-bridged binuclear gold(III) complexes on Na/K-ATPase activity: a joint experimental and theoretical approach (2017) (5)
- Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells. (2016) (5)
- Leaf Decoction of Carica papaya Combined with Artesunate Prevents Recrudescence in Plasmodium berghei-Infected Mice (2019) (4)
- NMR reveals the metabolic changes induced by auranofin in A2780 cancer cells: evidence for glutathione dysregulation. (2021) (4)
- EXAFS studies of Fe(III)-phosvitin at high metal to protein ratios (1994) (4)
- THALLIUM-205 AS AN NMR PROBE FOR THE INVESTIGATION OF TRANSFERRIN (1983) (4)
- Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections (2014) (4)
- Comparative Analysis of [Au(en)2]3+ and [Pt(en)2]2+ non Covalent Binding to Calf Thymus DNA (2000) (4)
- Ytterbium(III) as a CD probe for the investigation of the metal binding sites of transferrins (1986) (4)
- The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct. (2020) (4)
- The reaction of artemisinin with hemin: a further insight into the mechanism (2004) (4)
- Native mass spectrometry of human carbonic anhydrase I and its inhibitor complexes (2020) (4)
- Antiplasmodial in vivo activity of Carica papaya leaf decoction (2010) (4)
- Reactions with Proteins of Three Novel Anticancer Platinum(II) Complexes Bearing N-Heterocyclic Ligands (2021) (4)
- Protein metalation by two structurally related gold(I) carbene complexes: An ESI MS study (2021) (4)
- Peroxidase and superoxide dismutase activities in bean in response to ozone (1997) (4)
- Reactions of cytotoxic metallodrugs with lysozyme in pure DMSO explored through UV–Vis absorption spectroscopy and ESI MS (2015) (4)
- Role of aminoacidic residues inside active sites of metalloproteins (1988) (3)
- Modulation of the in vitro antimalarial effects of artemisinin by selected flavonoids and by reducing agents (2007) (3)
- Conjugates of Gold Nanoparticles and Antitumor Gold(III) Complexes as a Tool for Their AFM and SERS Detection in Biological Tissue (2019) (3)
- EXAFS INVESTIGATIONS ON A N-TERMINAL FRAGMENT OF HUMAN TRANSFERRIN CONTAINING A SINGLE IRON BINDING SITE (1986) (3)
- Medicinal Au(I) compounds targeting urease as prospective antimicrobial agents: unveiling the structural basis for enzyme inhibition. (2021) (3)
- Transferrin: A Natural Carrier for Metal Ions and Drugs (1997) (3)
- Modulation of the in vitro antimalarial effects of artemisinin by selected extracts: the case of olive leaf water extract (2008) (3)
- The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study (2022) (3)
- A multi-technique approach to predicting the molecular structure of cuprizone in the gas phase and in the crystalline state (2008) (3)
- Ruthenium-Sulfoxide Complexes with a Specific Antimetastatic Activity (1997) (2)
- Selenol (-SeH) as a target for mercury and gold in biological systems: Contributions of mass spectrometry and atomic spectroscopy (2022) (2)
- (S)-(+)-2-[2-(Biphenyl-2-yl)-1-methylethyl]-4,5-dihydro-1H-imidazolium hydrogen oxalate (2005) (2)
- Cobalt(II) as a probe of the metal binding sites of transferrins (1990) (2)
- Systems Biology of the Proteomic Analysis of Cytotoxic Gold Compounds in A2780 Ovarian Cancer Cell Line: A Network Analysis (2016) (2)
- 1H NMR studies on reduced high potential iron protein (HIPIP) from Chromatium Vinosum (1993) (2)
- Interactions of the organogold(III) compound Aubipyc with the copper chaperone Atox1: a joint mass spectrometry and circular dichroism investigation (2015) (2)
- EXAFS studies on copper transferrin (1992) (2)
- Platinum-Based Anticancer Drugs: Unveiling Novel Mechanisms of Action of Conventional Metallodrugs for Improved Therapies. (2021) (2)
- Cyclodextrin Inclusion Complexes of Auranofin and Its Iodido Analog: A Chemical and Biological Study (2021) (2)
- Ruthenium(II) 1,4,7-trithiacyclononane complexes of curcumin and bisdemethoxycurcumin: Synthesis, characterization, and biological activity. (2021) (2)
- Dinuclear Gold(III) Complexes as Potential Anticancer Agents: Structure, Reactivity and Biological Profile of a Series of Gold(III) Oxo-BridgedDerivatives (2010) (2)
- Synthesis, chemical characterization, and biological evaluation of a novel auranofin derivative as an anticancer agent. (2022) (2)
- Rapid and efficient purification of hypericin and pseudohypericin and inhibition of thioredoxin reductase (2009) (2)
- Comparative NMR metabolomics of the responses of A2780 human ovarian cancer cells to clinically established Pt-based drugs. (2022) (1)
- Interplay of crystallography, Raman microspectroscopy and electrospray mass spectrometry for studying the reaction between ruthenium complexes and proteins (2014) (1)
- Correction to: Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin (2019) (1)
- Chemical Modification of Auranofin Yields a New Family of Anticancer Drug Candidates: The Gold(I) Phosphite Analogues (2023) (1)
- A 1H NMR study of cobalt(II) arsanilazocarboxypeptidase A. (1989) (1)
- Large Protein Assemblies for High-Relaxivity Contrast Agents: The Case of Gadolinium-Labeled Asparaginase (2022) (1)
- Evaluation of Auranofin Loading within Ferritin Nanocages (2022) (1)
- New platinum(II) and palladium(II) complexes with substituted terpyridine ligands: synthesis and characterization, cytotoxicity and reactivity towards biomolecules (2018) (1)
- Direct detection of iron clusters in L ferritins through ESI-MS experiments. (2021) (1)
- Correction to Promising in Vitro anti-Alzheimer Propertiesfor a Ruthenium(III) Complex (2013) (1)
- Recent trends in antitumor gold(III) complexes : Innovative cytotoxic metallodrugs for cancer treatment (2005) (1)
- Comparative reactivity of medicinal gold(I) compounds with the cyclic peptide vasopressin and its diselenide analogue. (2021) (1)
- Time course of antioxidant enzymes in the paraquat-resistant and tolerant Heary fleabane (Conyza bonariensis) biotypes in response to ozone exposure and paraquat application (2019) (1)
- Computationally enhanced X-ray diffraction analysis of a gold(III) complex interacting with the human telomeric DNA G-quadruplex. Unravelling non-unique ligand positioning. (2022) (1)
- Reactions of Arsenoplatin-1 with Protein Targets: A Combined Experimental and Theoretical Study (2022) (1)
- X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme (2007) (0)
- The Metal-binding Properties of Ovotransferrin (2001) (0)
- Reactivity of CORM [RuII(CO)3Cl2{N-(N1-methylbenzimidazole)}] with aminoacids. Synthesis, and analytical and structural study for the new binuclear cis-[RuI(CO)2(N-MBI)(μ2-O,O-BAL)]2 sawhorse complex at solid state and in solution (2019) (0)
- The influence of oxo-bridged binuclear gold(III) complexes on Na/K-ATPase activity: a joint experimental and theoretical approach (2017) (0)
- Bottom-up mass spectrometry proteomics strategies for the identification of metallodrug binding sites on proteins: the search for a general protocol to assess adduct stability (2015) (0)
- Reactions of proteins with a few organopalladium compounds of medicinal interest (2022) (0)
- Antitumor gold(III) complexes (2005) (0)
- Ferritin-based anticancer metallodrug delivery: Encapsulation of Arsenoplatin-1 within the ferritin nanocage (2020) (0)
- Frontispiece: Protein Metalation by Anticancer Metallodrugs: A Joint ESI MS and XRD Investigative Strategy (2017) (0)
- Mono- and Binuclear Gold Based Complexes with Anti-tumoral Properties (2012) (0)
- Synergistic antiplasmodial activity of artemisinin and olive leaf decoction: the role of the constituents of the phytocomplex (2009) (0)
- 2D 1H NMR investigations of paramagnetic proteins: The oxidized form of ferredoxin from clostridium pasteurianum. (1991) (0)
- Erratum: Leaf Decoction of Carica papaya Combined with Artesunate Prevents Recrudescence in Plasmodium berghei-Infected Mice (2019) (0)
- Gold complexes as potential antimalarial agents (2012) (0)
- Reactions of cytotoxic metallodrugs with lysozyme in pure DMSO explored through UV–Vis absorption spectroscopy and ESI MS (2015) (0)
- Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme (2012) (0)
- The Dependence of the Copper Dissociation Rate Constants from Human(Serum)- and Ονο-Transferrin on pH and the Anions (1999) (0)
- Xray structure of cisplatin-protein interactions: selective platination of his 19 in superoxide dismutase (2006) (0)
- Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents (2017) (0)
- Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles (2016) (0)
- Proton NMR and NOE studies on the cobalt(II) derivative of rabbit metallothionein (1989) (0)
- Synthesis and structural characterization of new mono and dinuclear gold(I) complexes as potential antitumor agents (2010) (0)
- New gold carbene complexes as candidate anticancer agents (2016) (0)
- Mass Spectrometry and Metallomics: binding site location in the Cyt c-CDDP model system (2017) (0)
- Biological studies on a new class of gold complexes with pyridinyl-benzoimidazole (2010) (0)
- Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles (2016) (0)
- Exploring metal complexes-protein/peptide interactions by high resolution mass spectrometry (2009) (0)
- X-ray structure of the adduct formed between hen egg white lysozyme and NAMI-A (2014) (0)
- Exploring the interactions between phosphane-based platinum(II) dichlorides and cytochrome c by electrospray ionization high resolution mass spectrometry (2011) (0)
- Solution structure of a human G-Quadruplex hybrid-2 form in complex with a Gold-ligand. (2017) (0)
- Superoxide dismutase and peroxidase activities in bean leaves folowing acute ozone stress (1996) (0)
- X-ray Structure of the Adduct formed between cisplatin and Ribonuclease A (2014) (0)
- ESI–MS studies of the reactions of novel platinum(II) complexes containing O,O′-chelated acetylacetonate and sulfur ligands with selected model proteins (2017) (0)
- An EXAFS study on the interaction between serum transferrin and oxalate as synergistic anion (1989) (0)
- The crystal structure of a NAMI A-Carbonic Anhydrase II adduct discloses the mode of action of this novel anticancer metallodrug (2011) (0)
- First Crystal Structure for an Oxaliplatin-Protein Complex (2015) (0)
- Supporting Information Crystal X-ray Structure for the Complex formed in the Reaction between Oxaliplatin and Lysozyme (2014) (0)
- Correction: Reactions of metallodrugs with proteins: selective binding of phosphane-based platinum(ii) dichlorides to horse heart cytochrome c probed by ESI MS coupled to enzymatic cleavage. (2018) (0)
- Xray structure of cisplatin-protein interactions (2006) (0)
- Interactions of the organogold(III) compound Aubipyc with the copper chaperone Atox1: a joint mass spectrometry and circular dichroism investigation (2015) (0)
- Mass spectrometry and metallomics: stability and binding site location in the Cyt c-CDDP model system (2016) (0)
- CCDC 193259: Experimental Crystal Structure Determination (2002) (0)
- Coordination Modes of Histidine. Part 10. Iron(III) Tyrosinate Models. Synthesis and Spectroscopic and Stereochemical Studies of Iron(III) Complexes of N-Salicylidene-L-amino Acids. (1987) (0)
- Gold-Based Metal Drugs as Inhibitors of Coronavirus Proteins: The Inhibition of SARS-CoV-2 Main Protease by Auranofin and Its Analogs (2022) (0)
- Synthesis, structural characterization and in vitro cytotoxicity of gold complexes with 2-(2-pyridyl)benzimidazole. Gold(III) vs. Gold(I), mononuclear vs. binuclear derivatives (2011) (0)
- Crystal structure of cisplatinated bovine Cu,Zn superoxide dismutase (2006) (0)
- Studies of cytotoxic gold compounds: interactions with model proteins and with the copper chaperone Atox-1 (2012) (0)
- A biophysical study of the interactions of palladium(II), platinum(II) and gold(III) complexes of aminopyridyl-2,2'-bipyridine ligands with RNAs and other nucleic acid structures. (2022) (0)
- Novel gold(I)/gold(III) compounds bearing saccharinate ligands: structural and solution chemistry, protein binding behaviour and antiproliferative effects (2009) (0)
- XAS/XRD complementary data on metallodrugs and their proteins complexes (2011) (0)
- Structure of the complex of a human telomeric DNA with Au(caffein-2-ylidene)2 (2016) (0)
- CCDC 753959: Experimental Crystal Structure Determination (2011) (0)
- Structural evidences for a secondary gold binding site in the hydrophobic box of lysozyme (2015) (0)
- Interaction of the antitumour ruthenium(III) complex trans-indazolium[tetrachlorobisindazoleruthenate(III)] with apotransferrin (1993) (0)
- Reviewers of the Journal of Chemotherapy (2010) (0)
- Catalytic and Biological studies of Au(III) complexes with pyridinyl-oxazoline ligands (2010) (0)
- Triethylphosphine gold iodide (I), the iodido analogue of Auranofin: comparative studies of a potential antineoplastic agent (2016) (0)
- A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition (2011) (0)
- Jacobs Journal of Bioinformatics and Proteomics Systems Biology of the Proteomic Analysis of Cytotoxic Gold Compounds in A 2780 Ovarian Cancer Cell Line : A Network Analysis (2016) (0)
- Electron transfer complexes: Experimental mapping of the redox-dependent cytochrome c electrostatic surface (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Luigi Messori?
Luigi Messori is affiliated with the following schools:
